The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants
Top Cited Papers
- 1 December 2002
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 4 (4) , 195-200
- https://doi.org/10.1034/j.1399-3062.2002.t01-2-02002.x
Abstract
Background. Invasive aspergillosis (IA) is associated with significant morbidity and mortality in solid organ transplant recipients but data on the incidence rates stratified by type of solid organ are limited. Objective. To describe the attack rates and incidence of IA in solid organ transplant recipients, and the impact of universal Aspergillus prophylaxis (aerosolized amphotericin B or oral itraconazole) in lung transplant recipients. Patients. The 2046 patients who received solid organ transplants at the Cleveland Clinic Foundation from January 1990 through 1999 were studied. Methods. Cases were ascertained through computerized records of microbiology, cytology, and pathology reports. Definite IA was defined as a positive culture and pathology showing septate hyphae. Probable IA was clinical disease and either a positive culture or histopathology. Disseminated IA was defined as involvement of two or more noncontiguous anatomic sites. Results. We identified 33 cases of IA (28% disseminated) in 2046 patients (attack rate = 1.6%) for an incidence of 4.8 cases per 1000 patient‐years (33 cases/6813 pt‐years). Both the attack and the incidence rates were significantly higher for lung transplant recipients vs. other transplant recipients: lung 12.8% (24 cases/188 patients) or 40.5 cases/1000‐pt year vs. heart 0.4% (3/686) or 1.4 per 1000‐pt year vs. liver 0.7% (3/439) or 2.1 per 1000‐pt year vs. renal 0.4% (3/733) or 1.2 per 1000‐pt year (P < 0.01). The incidence of IA was highest during the first year after transplantation for all categories, but cases occurred after the first year of transplantation only in lung transplant recipients. The attack rate of IA in lung transplant recipients was significantly lower after institution of routine Aspergillus prophylaxis (4.9% vs. 18.2%, P < 0.05). Conclusions. The highest incidence and attack rate of invasive aspergillosis among solid organ transplant recipients occurs in lung transplant recipients and supports the routine use of Aspergillus prophylaxis for at least one year after transplantation in this group.Keywords
This publication has 18 references indexed in Scilit:
- Enhanced cyclosporine-itraconazole interaction with cola in lung transplant recipientsClinical Transplantation, 2001
- Antifungal Prophylaxis for Solid Organ Transplant Recipients: Seeking Clarity Amidst ControversyClinical Infectious Diseases, 2000
- Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosisBone Marrow Transplantation, 1999
- Antifungal Prophylaxis During the Early Postoperative Period of Lung TransplantationChest, 1999
- Pre-emptive therapy with azoles in lung transplant patientsEuropean Respiratory Journal, 1999
- Aspergillus INFECTION IN SINGLE AND DOUBLE LUNG TRANSPLANT RECIPIENTSTransplantation, 1996
- Risk factors for systemic fungal infections in liver transplant recipientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1995
- Use of amphotericin B aerosols for the prevention of pulmonary aspergillosisInfection, 1994
- Ulcerative Tracheobronchitis after Lung Transplantation: A New Form of Invasive AspergillosisAmerican Review of Respiratory Disease, 1991
- Infectious Complications in Heart Transplant Recipients Receiving Cyclosporine and CorticosteroidsAnnals of Internal Medicine, 1987